详细内容或原文请订阅后点击阅览
NITI Aayog 提议未来自由贸易协定的制药章节，敦促印度向价值链上游移动
Niti Aayog 提出了自由贸易协定蓝图，以提高印度制药行业监管的可预测性。该智库敦促向高价值领域转变，强调加强产学合作，促进专利商业化和初创企业孵化。虽然印度是“世界制药厂”，但它需要通过专注于深度技术创新来提升价值链，成为制药创新之都。
来源:经济时报New Delhi:
提出了关于
作为未来的蓝图
改进
, while urging India to diversify into high-value pharmaceutical segments.
在第八版《贸易观察季刊》中，Aayog 支持提高监管透明度和加强行业学术界
生命科学集群加速发展
, research collaboration and startup incubation.
报告还呼吁将环境合规性从个体企业转向共享基础设施，称更严格的环境要求显着增加了制造和研发成本。
It noted that India's pharma supply chain remains heavily dependent on China for critical
(APIs) and key starting materials, with 65% of such imports sourced from the country.
Weak innovation and commercialisation ecosystems, it said, have created uncertainty for innovators and long-term investment.
Niti Aayog VC Ashok Kumar Lahiri said India is widely regarded as the pharmacy of the world.
“Niti Aayog 发现，虽然我们在制药行业的销量方面做得不错，但我们需要向价值链上游移动，”Lahiri 说。 India has built credibility in global markets and its pharmaceutical companies should be able to command a larger international presence if they offer high-quality, competitively priced branded products, he said.
"As global market dynamics rapidly shift towards high value, knowledge-intensive
，印度必须通过深度技术创新来补充其传统制造规模……才能从世界制药厂成为无可争议的制药创新之都，”报告称。
印度供应价格实惠
to markets around the world, meeting about 50% of Africa's, 40% of the US' and 25% of the UK's generic drug requirements.